Can ashwagandha cause hair loss? 5/7/2021
Ashwagandha is generally considered safe for hair while on Dutasteride, as its effects on testosterone are minimal and it may reduce anxiety. Some users report positive effects on hair thickness and anxiety reduction when using ashwagandha alongside finasteride.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity I cannot sleep anymore, what should I do
Finasteride may cause sleep disturbances, with some users experiencing insomnia. Reducing the dosage, switching brands, or trying Dutasteride might help.
community Does ashwagandha work against finasteride?
Finasteride may cause insomnia, and ashwagandha is suggested to help with sleep issues without significantly affecting testosterone or DHT levels. Users discuss personal experiences with sleep disturbances and suggest consulting a doctor if side effects persist.
community How concerned should I be about the Testosterone (and thus resultant DHT) spike from Ashwagandha, as a Dutasteride user?
Ashwagandha may increase testosterone, which can convert to DHT and potentially affect hair loss, but using dutasteride should mitigate this concern. Users suggest that occasional Ashwagandha use is unlikely to impact hair loss significantly when on dutasteride.
community Dutasteride absolutely nukes hair DHT
Dutasteride significantly reduces DHT levels, potentially more effectively than finasteride, and is used to treat hair loss. Some users report side effects like reduced libido and mood changes, while others experience hair regrowth and increased testosterone.
community Is it okay if I try ashwagandha?
The conversation discusses the potential effects of ashwagandha on hair loss and anxiety, with users sharing mixed experiences. Some users caution against ashwagandha due to its potential to increase testosterone and DHT, which could counteract finasteride's benefits, while others suggest alternative methods like exercise, cold showers, or different supplements for managing anxiety.
Related Research
6 / 6 results
research Androgenetic Alopecia: Therapy Update
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
research Androgenetic alopecia: An update
This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.
research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies
This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.
research Evaluation of the Hair Growth-Promoting Effects of Combined Treatment with Hair Growth Stimulants
This study from years of treating hair loss in Japan reported various treatment outcomes: some patients showed improvement with manual treatment alone, others with added finasteride, some did not respond to either, and some maintained benefits even after stopping finasteride.
research Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics
This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.
research Uma revisão integrativa sobre o tratamento da alopecia com plantas medicinais, fitoterápicos e suplementos alimentares
This integrative literature review investigated clinical trials on using medicinal plants, herbal products, and dietary supplements for treating alopecia, noting a need for further studies due to limited chemical-pharmaceutical analyses of the plant species involved, which include Allium sativum and Rosmarinus officinalis.